Key insights
- H.C. Wainwright reiterated a Buy rating for Evaxion Biotech (EVAX) with a $16 price target, implying substantial upside. The analysis highlights positive data from Evaxion's personalized vaccine strategy for glioblastoma and promising results from its phase 2 trial for melanoma treatment in combination with Merck's Keytruda. While positive, the impact on the broader US equity market is limited due to the company's small market capitalization and the early stage of the drug development.
Investing.com - H.C. Wainwright reiterated a Buy rating on Evaxion Biotech (NASDAQ:EVAX) with a $16.00 price target. With shares currently trading at $4.25, this represents potential upside of 276%, particularly notable given the stock’s impressive 167% return over the past year.
The firm commented on data presented at the 2026 annual meeting of American Association for Cancer Research. Evaxion, in collaboration with Duke University, presented a personalized vaccine strategy for glioblastoma using 24 tumor samples.
The vaccines were designed using the company’s AI-Immunology platform. The PIONEER model identified tumor neoantigens and the ObsERV model identified endogenous retroviruses-derived tumor antigens.
The platform identified more than four times as many ERV-derived antigens as neoantigens, at 81% versus 19%. The platform designed personalized vaccines for each patient sample with up to 13 antigens per proposed vaccine.
Of the 24 proposed designs, 21 used both ERV antigens and neoantigens, one used ERV-only, and two used neoantigen-only.
In other recent news, Evaxion A/S reported significant developments in its phase 2 trial for the personalized cancer vaccine EVX-01. The company announced that the trial achieved an 86% success rate in triggering tumor-specific immune responses, a promising result for patients with advanced melanoma. This trial was conducted in combination with Merck’s Keytruda, and the data will be presented at the American Association for Cancer Research Annual Meeting in San Diego in April 2026. Additionally, Evaxion completed a one-year extension of the phase 2 trial, with the last patient having completed their final physician visit. The company expects to present three-year clinical efficacy data in the second half of 2026. In another development, Evaxion showcased its AI-Immunology platform’s ability to identify vaccine targets for glioblastoma, collaborating with Duke University School of Medicine. The findings for this deadly brain cancer, which has limited treatment options, will also be presented at the upcoming annual meeting. These updates highlight Evaxion’s ongoing efforts in advancing cancer vaccine research.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.